• Pedro Mata, Rodrigo Alonso, Antonio Ruíz-Garcia, Jose L Díaz-Díaz, Noemí González, Teresa Gijón-Conde, Ceferino Martínez-Faedo, Ignacio Morón, Ezequiel Arranz, Rocío Aguado, Rosa Argueso, and Leopoldo Perez de Isla.
• Fundación Hipercolesterolemia Familiar, Madrid, España. Electronic address: pmata@colesterolfamiliar.org.
• Aten Primaria. 2014 Oct 1; 46 (8): 440-6.

AbstractFamilial combined hyperlipidemia (FCH) is a frequent disorder associated with premature coronary artery disease. It is transmitted in an autosomal dominant manner, although there is not a unique gene involved. The diagnosis is performed using clinical criteria, and variability in lipid phenotype and family history of hyperlipidemia are necessaries. Frequently, the disorder is associated with type2 diabetes mellitus, arterial hypertension and central obesity. Patients with FCH are considered as high cardiovascular risk and the lipid target is an LDL-cholesterol <100mg/dL, and <70mg/dL if cardiovascular disease or type 2 diabetes are present. Patients with FCH require lipid lowering treatment using potent statins and sometimes, combined lipid-lowering treatment. Identification and management of other cardiovascular risk factors as type 2 diabetes and hypertension are fundamental to reduce cardiovascular disease burden. This document gives recommendations for the diagnosis and global treatment of patients with FCH directed to specialists and general practitioners. Copyright © 2014 Elsevier España, S.L.U. All rights reserved.

12 keywords...

hide…